CD8A and neoplasm: The high expression of ICB predictive signatures and the enhanced density at tumor site of CD8+ T cell subsets known to be associated with response to immunotherapy (such as the TPEX), suggests that patients with LOW lesions might have increased responsiveness to ICB.